Golimumab

(Simponi®)

Simponi®

Drug updated on 9/13/2023

Dosage FormInjection (subcutaneous; 50 mg/0.5 mL, 100 mg/mL)
Drug ClassTumor necrosis factor (TNF) blocker
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.
  • Active psoriatic arthritis (PsA) alone, or in combination with methotrexate.
  • Active ankylosing spondylitis (AS).
  • Moderate to severe ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy: inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, inducing clinical remission, and achieving and sustaining clinical remission in induction responders.

Product Monograph / Prescribing Information

Document TitleYearSource
Simponi (golimumab) Prescribing Information.2019Janssen Biotech, Inc. Horsham, PA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines